Deal appetite across the manufacturing sector remains above market parity, but momentum is fading, making precise intelligence about where activity is concentrated increasingly critical for deal makers.
Fintent’s financial-intent data shows manufacturing’s M&A Propensity currently sits at 1.12, with CapRaise Propensity at 1.09, where a reading of 1.00 represents market parity across the broader company universe.
Both indices have declined over the last 30 days following a Q3 2025 peak of 1.28, with the four-quarter momentum slope now registering negative at -0.05 on M&A and -0.01 on CapRaise.
The propensity index measures how much deal-related research activity a cohort generates relative to peers, capturing behavior such as engaging investment banks, running valuations, and scoping financing structures.
Three sub-sectors stand out as the clearest concentration of deal appetite: Biotechnology Research at an M&A Propensity of 2.42, Laboratory Equipment at 1.52, and Aerospace and Defense at 1.38.
Biotechnology Research commands the highest reading by a significant margin, more than double peer parity, while its low CapRaise Propensity of 0.53 signals a cohort being consolidated and acquired rather than raising fresh capital.
Laboratory Equipment is notable for its positive momentum of +0.10, meaning deal-preparation activity is still accelerating, making early identification of targets especially valuable given the smaller universe of 1,140 tracked companies.
Aerospace and Defense is the only focus sub-sector running hotter on CapRaise at 1.53 than on M&A at 1.38, reflecting a structural rearmament build-out supported by NATO’s March 26, 2026 annual report showing every member meeting or exceeding the 2% of GDP defense-spending target for the first time.
Chemical Manufacturing and Supply is the sector’s clearest laggard, with M&A Propensity falling to 0.74 and CapRaise Propensity to 0.62, weighed down by regulatory pressure stemming from the EPA’s April 10, 2024 PFAS drinking-water rule and the designation of PFOA/PFOS as CERCLA hazardous substances.
The broader manufacturing cohort tracked by Fintent spans 54,500 companies, compared quarterly against similarly-sized firms across the wider universe, with the propensity index calculated as the cohort’s signal density divided by a peer baseline.
Earlier macro turbulence is visible in the data, as the Q2 2025 softening aligned with US manufacturing contraction when the ISM PMI fell below 50 from April through June amid tariff uncertainty, before recovering in line with the Federal Reserve’s September 17, 2025 rate cut of 25 basis points.
Fintent tracks 5,829 Biotechnology Research companies, 4,226 Aerospace and Defense companies, and 1,140 Laboratory Equipment companies in the middle market, defined as firms with 25 to 1,000 employees.
Over the last month, 36 of those middle-market companies crossed an M&A score of 50 or higher, with 18 in Biotechnology Research, 15 in Aerospace and Defense, and 3 in Laboratory Equipment flagging dense clusters of deal-preparation signals.
A score at that threshold reflects recent activity including bankers engaged, valuations completed, and financing scoped, representing the sector’s upcoming transactions before any formal announcements are made.